Tác giả (2)
- Cost-utility Analysis of Regorafenib for Patients With Hepatocellular Carcinoma who Progressed on Sorafenib: Evidence From a Lower-Middle-Income Country 2026
- A systematic review of health economic evaluations of PD-(L)1 inhibitors for first-line treatment among patients with high PD-L1 expression non-small cell lung cancer 2024